Rezolute provides update on its phase 3 sunrize study of ersodetug for the treatment of hypoglycemia due to congenital hyperinsulinism

Open-label arm (infant participants < 1 year old) has been recently reviewed by a data monitoring committee (dmc) and target drug concentrations were safely reached at tested doses

RZLT Ratings Summary

RZLT Quant Ranking